Acorn Bioventures Updates Cardiff Oncology Stake

TL;DR

**Acorn Bioventures just updated their stake in Cardiff Oncology, signaling a potential shift in their investment thesis.**

AI Summary

Acorn Bioventures, L.P. filed an amended Schedule 13G/A on February 6, 2024, indicating a change in their beneficial ownership of Cardiff Oncology, Inc. common stock as of December 31, 2023. While the filing doesn't specify the exact change in share count or percentage, it signals an update to their previous holdings. This matters to investors because significant changes in institutional ownership can influence stock price and reflect a major investor's updated confidence (or lack thereof) in the company's future prospects.

Why It Matters

Changes in major institutional holdings can signal shifts in investor confidence and potentially impact stock price, as large buyers or sellers can create significant market movements.

Risk Assessment

Risk Level: low — This filing is an update to an existing stake, not a new, aggressive position, making it a lower risk event.

Analyst Insight

An investor should monitor subsequent filings from Acorn Bioventures or Cardiff Oncology's proxy statements to understand the exact nature of the change in ownership (increase or decrease) and its potential implications for the stock's future performance.

Key Players & Entities

• Acorn Bioventures, L.P. (company) — the reporting person updating its beneficial ownership
• Cardiff Oncology, Inc. (company) — the issuer whose securities are being reported
• December 31, 2023 (date) — the date of the event requiring the filing
• February 6, 2024 (date) — the filing date of the SC 13G/A
• 14147L108 (other) — the CUSIP number for Cardiff Oncology, Inc. Common Stock

FAQ

Key Financial Figures

• $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of

Filing Documents

• p24-0480sc13ga.htm (SC 13G/A) — 73KB
• 0000902664-24-001100.txt ( ) — 75KB

(a)

Item 1(a). Name of Issuer. Cardiff Oncology, Inc. (the " Issuer ")

(b)

Item 1(b). Address of Issuer's Principal Executive Offices. 11055 Flintkote Avenue San Diego, California 92121

(a)

Item 2(a). Name of Person Filing. This statement is filed by: (i) Acorn Bioventures, L.P. (" Acorn "); (ii) Acorn Capital Advisors GP, LLC (" Acorn GP "), which is the sole general partner of Acorn; and (iii) Anders Hove (" Hove "), who is the manager of Acorn GP. The foregoing persons are hereinafter sometimes collectively referred to as the " Reporting Persons ." The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.

(b)

Item 2(b). Address of Principal Business Office. The address of the principal business office of each of the Reporting Persons is 420 Lexington Avenue, Suite 2626, New York, New York 10170

(c)

Item 2(c). Place of Organization. Acorn is a Delaware limited partnership. Acorn GP is a Delaware limited liability company. Hove is a citizen of the United States of America.

(d)

Item 2(d). Title of Class of Securities. Common stock, $0.0001 par value per share (the " Common Stock ")

(e)

Item 2(e). CUSIP Number. 14147L108 CUSIP No. 14147L108 13G/A Page 6 of 8 Pages Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a: (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F); (g) o A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J); (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: __________________________ Item 4. The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The percentages set forth herein are calculated based on 44,677,169 shares of the Company's common stock, par value $0.0001 per share outstanding as of October 26, 2023, as set forth in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023 and filed with th

View Full Filing

View this SC 13G/A filing on SEC EDGAR